ID: ALA4529610

Max Phase: Preclinical

Molecular Formula: C15H16BrN

Molecular Weight: 290.20

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CN(Cc1ccccc1)Cc1ccc(Br)cc1

Standard InChI:  InChI=1S/C15H16BrN/c1-17(11-13-5-3-2-4-6-13)12-14-7-9-15(16)10-8-14/h2-10H,11-12H2,1H3

Standard InChI Key:  WLJJUAITCXDCGG-UHFFFAOYSA-N

Associated Targets(Human)

Pyrroline-5-carboxylate reductase 1, mitochondrial 71 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 290.20Molecular Weight (Monoisotopic): 289.0466AlogP: 4.08#Rotatable Bonds: 4
Polar Surface Area: 3.24Molecular Species: NEUTRALHBA: 1HBD: 0
#RO5 Violations: 0HBA (Lipinski): 1HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.44CX LogP: 4.41CX LogD: 3.33
Aromatic Rings: 2Heavy Atoms: 17QED Weighted: 0.82Np Likeness Score: -1.09

References

1. Milne K, Sun J, Zaal EA, Mowat J, Celie PHN, Fish A, Berkers CR, Forlani G, Loayza-Puch F, Jamieson C, Agami R..  (2019)  A fragment-like approach to PYCR1 inhibition.,  29  (18): [PMID:31362921] [10.1016/j.bmcl.2019.07.047]

Source